This Friday, the European Commission authorized the marketing of a new adaptation, the third, of the Spikevax vaccine against Covid-19, from the pharmaceutical company Moderna.
Spikevax
Marketing authorization was granted through an accelerated procedure, after the European Medicines Agency gave a positive evaluation.
In Portugal, vaccination will begin on September 29 and will be carried out simultaneously in community pharmacies, for people aged 60 or over, and in health establishments of the National Health Service (SNS), for people under 60 years of age and with risk diseases. . .
On September 7, the European Center for Disease Prevention and Control (ECDC) warned of the recent increase in transmission of the Covid-19 virus in the European Union and the European Economic Area (EU/EEA).
“In recent weeks, signs of SARS-CoV-2 transmission have increased from previously very low levels in the EU and EEA,” the European agency said in a statement.
Covid-19 is a pandemic respiratory disease caused by the SARS-CoV-2 coronavirus, a type of virus detected at the end of 2019 in China and which has assumed several variants and subvariants, some more contagious than others.
Source: TSF
